Also known as: Benlysta (brand)
Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), used in the treatment of active systemic lupus erythematosus (SLE) and lupus nephritis. It reduces the survival of B cells, decreasing autoantibody production. Mediocon Inc supplies pharmaceutical-grade Belimumab for biopharmaceutical manufacturers.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Purity | ≥ 99% (by SEC-HPLC) |
| Endotoxin | NMT 1 EU/mg |
| Bioburden | Complies |
| Identification | Peptide Mapping Compliant |
| Storage | 2–8°C |
| Packing | As per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Belimumab (CAS 356547-88-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Belimumab is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance